{'fraction_non_alphanumeric': 0.011182108626198083, 'fraction_numerical': 0.01437699680511182, 'mean_word_length': 5.207920792079208, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Glucagon for Injection

In accordance with the Rules and Procedures of the 2015–2020 Council of Experts, the Biologics Monographs 1—Peptides and Insulins Expert Committee has revised the Glucagon for Injection monograph. This revision was requested following the FDA approval of a synthetic glucagon product with the same name as the recombinant product. The purpose for the revision is to update the Labeling section to state that the material is of recombinant DNA or of synthetic origin. An additional revision will be proposed for public comment in the future with additional requirements for products of synthetic origin.